Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer’s disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/β-catenin pathway
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Currently, Alzheimer's disease (AD) cannot be treated effectively. Mesenchymal stem cells (MSCs)-derived extracellular vesicles (EVs) (MSC-EVs) exhibit therapeutic effects on many diseases. This study investigated the mechanism of bone marrow MSC-EVs (BM-MSC-EVs) in a rat model of AD. The cognitive function, amyloid-β (Aβ) plaques, Aβ deposition areas and levels of Aβ1-42, Aβ decomposition-related factors (NEP and IDE), and inflammatory cytokines in BM-MSC-EVs-treated AD rats were measured. The effect of BM-MSC-EVs was studied in AD neuron model. microRNA (miR)-29c-3p and BACE1 expression, as well as levels of Wnt/β-catenin pathway-related factors in AD and EVs-treated AD models were detected. miR-29c-3p relationship with BACE1 was predicted and confirmed. miR-29c-3p and BACE1 were interfered to verify the mechanism of EVs in AD. The Wnt/β-catenin pathway inhibitor DKK1 was further added to EVs-treated AD neurons. BM-MSC-EVs showed therapeutic effects on AD rats and neurons. BM-MSC-EVs carried miR-29c-3p into AD neurons. miR-29c-3p targeted BACE1. Silencing miR-29c-3p in BM-MSCs reduced BM-MSC-EV therapeutic effect on AD, which was reversed after BACE1 knockdown. miR-29c-3p targeted BACE1 and activated the Wnt/β-catenin pathway, and the Wnt/β-catenin pathway inhibition impaired EV therapeutic effects on AD. We highlighted that BM-MSC-EVs delivered miR-29c-3p to neurons to inhibit BACE1 expression and activate the Wnt/β-catenin pathway, thereby playing a therapeutic role in AD. This study may provide a novel perspective for elucidating the mechanism of MSCs in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1×
“Alzheimer’s disease (AD), a complex progressive neurodegenerative disorder, is the most common type of dementia worldwide and frequently accompanied by memory impairment, cognitive decline, disorientation, and even death [1, 2].”
BackgroundReassessment of exosome composition
Jeppesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., Zimmerman, L. J., Liebler, D. C., Ping, J., Liu, Q., Evans, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.029 · Cited by 2,975
Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease
Jia, L., Piña-Crespo, J., & Li, Y. (2019) · Molecular Brain · doi:10.1186/s13041-019-0525-5 · Cited by 288 · cited 1×
“Activation of the Wnt/β-catenin signaling suppresses Aβ production and tau protein hyperphosphorylation in the brain, and critically, restoring Wnt/β-catenin signaling represents a unique target for the design of novel AD therapies [56].”
BackgroundAlzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113 · cited 1×
“AD is an irreversible progressive neurodegenerative disease and causes typical cognitive impairment with no effective treatment currently [38, 39].”
BackgroundWnt/β-Catenin Signaling in Alzheimer’s Disease
Ferrari, G., Avila, M., Medina, M., Perez-Palma, E., Bustos, B., & Alarcon, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527312666131223113900 · Cited by 95
Mesenchymal Stem Cell Therapy and Alzheimer’s Disease: Current Status and Future Perspectives
Kim, J., Lee, Y., Lee, S., Kim, K., Song, M., & Lee, J. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200219 · Cited by 73
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Khalil, M. N. A., Choucry, M. A., El Senousy, A. S., Hassan, A., El-Marasy, S. A., El Awdan, S. A., & Omar, F. A. (2019) · PLOS ONE · doi:10.1371/journal.pone.0219378 · Cited by 25 · cited 1×
“Likewise, as has been demonstrated, downregulated BACE1 is tightly linked to the decrease of Aβ production and deposition, and eventually to the reduction of inflammation and neuron apoptosis [54].”
Background
Cited by
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
Palanisamy, C. P., Pei, J., Alugoju, P., Anthikapalli, N. V. A., Jayaraman, S., Veeraraghavan, V. P., Gopathy, S., Roy, J. R., Janaki, C. S., Thalamati, D., et al. (2023) · Theranostics · doi:10.7150/thno.83066 · Cited by 165
“miR-29c-3p targeted BACE1 and activated the Wnt/β-catenin pathway, and the Wnt/β-catenin pathway inhibition impaired EV therapeutic effects on AD [183].”
BackgroundLiang, Y., Iqbal, Z., Lu, J., Wang, J., Zhang, H., Chen, X., Duan, L., & Xia, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.10.008 · Cited by 162
Giovannelli, L., Bari, E., Jommi, C., Tartara, F., Armocida, D., Garbossa, D., Cofano, F., Torre, M. L., & Segale, L. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.06.013 · Cited by 102
“The effectiveness of MSC-secretome and EVs following intracerebral [83–86], intravenous [87–91], or intranasal [92–95] administration was assessed on transgenic animal models reporting mutations associated with AD [83,84,87–91,93–95], or injected with Aβ1-42 oligomers [85, 86] (Table 3).”
BackgroundMethodExtracellular vesicles in Alzheimer’s disease: from pathology to therapeutic approaches
Thakor, A., & Garcia-Contreras, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.343882 · Cited by 41
“This neuroprotection can be mediated by the delivery of MSC-EV specific cargo such as miR-29c-3p to neurons, which then inhibits BACE1 expression while activating the Wnt/β-catenin pathway (Sha et al., 2021).”
BackgroundNong, W., Bao, C., Chen, Y., & Wei, Z. (2022) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.6723 · Cited by 14
Metadata
- Authors
- Sha, S., Shen, X., Cao, Y., & Qu, L.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2021-06-04
- Volume
- 13
- Issue
- 11
- Pages
- 15285-15306
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W3165338446
- Cited by
- 107
- References
- 8
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.